- α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders
-
Taku Hatano, Ayami Okuzumi, Gen Matsumoto, Taiji Tsunemi, Nobutaka Hattori
-
J Mov Disord. 2024;17(2):127-137. Published online April 9, 2024
-
DOI: https://doi.org/10.14802/jmd.24075
-
-
3,147
View
-
340
Download
-
1
Web of Science
-
2
Crossref
-
 Abstract
 PDF
- Mutations in the SNCA gene, which encodes α-synuclein (α-syn), play a key role in the development of genetic Parkinson’s disease (PD). α-Syn is a major component of Lewy bodies in PD and glial cytoplasmic inclusions in multiple system atrophy (MSA). Rapid eye movement sleep behavior disorder patients often progress to PD, dementia with Lewy bodies, or MSA, which are collectively known as α-synucleinopathies. The loss of dopaminergic neurons with Lewy bodies precedes motor dysfunction in these diseases, but the mechanisms of neurodegeneration due to α-syn aggregation are poorly understood. Monitoring α-syn aggregation in vivo could serve as a diagnostic biomarker and help elucidate pathogenesis, necessitating a simple and accurate detection method. Seed amplification assays (SAAs), such as real-time quaking-induced conversion and protein misfolding cyclic amplification, are used to detect small amounts of abnormally structured α-syn protofibrils, which are central to aggregation. These methods are promising for the early diagnosis of α-synucleinopathy. Differences in α-syn filament structures between α-synucleinopathies, as observed through transmission electron microscopy and cryo-electron microscopy, suggest their role in the pathogenesis of neurodegeneration. SAAs may differentiate between subtypes of α-synucleinopathy and other diseases. Efforts are also being made to identify α-syn from blood using various methods. This review introduces body fluid α-syn biomarkers based on pathogenic α-syn seeds, which are expected to redefine α-synucleinopathy diagnosis and staging, improving clinical research accuracy and facilitating biomarker development.
-
Citations
Citations to this article as recorded by  - Selective detection of alpha synuclein amyloid fibrils by faradaic and non-faradaic electrochemical impedance spectroscopic approaches
Hussaini Adam, Subash C.B. Gopinath, Hemavathi Krishnan, Tijjani Adam, Makram A. Fakhri, Evan T. Salim, A. Shamsher, Sreeramanan Subramaniam, Yeng Chen
Bioelectrochemistry.2025; 161: 108800. CrossRef - Hypoxia Pathways in Parkinson’s Disease: From Pathogenesis to Therapeutic Targets
Yuanyuan Gao, Jiarui Zhang, Tuoxian Tang, Zhenjiang Liu
International Journal of Molecular Sciences.2024; 25(19): 10484. CrossRef
- Current Status of Telemedicine for Parkinson’s Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey
-
Mayuko Ogawa, Genko Oyama, Satoko Sekimoto, Taku Hatano, Nobutaka Hattori
-
J Mov Disord. 2022;15(1):58-61. Published online December 24, 2021
-
DOI: https://doi.org/10.14802/jmd.21096
-
-
5,374
View
-
241
Download
-
6
Web of Science
-
9
Crossref
-
Abstract
PDF
 Supplementary Material
- Objective
Using telemedicine is a way to improve the accessibility of specialists for patients with Parkinson’s disease (PD); however, it is not widely used in Japan. We investigated the efficacy of telemedicine in PD by using a single-center cross-sectional questionnaire survey.
Methods
We sent a questionnaire to patients who agreed to participate from among 52 patients with PD who had used telemedicine services at Juntendo University Hospital from October 2017 to November 2018. Caregivers were asked to respond to one question separately.
Results
A total of 38 patients responded to the questionnaire. Most patients were satisfied with the telemedicine consultation (7.8 ± 1.9), reporting that it was effective in reducing their travel burden. Twenty-one patients attended a telemedicine consultation with their caregivers, and their satisfaction was high (8.4 ± 1.8).
Conclusion
In a specific cohort in Japan, patients with PD and their caregivers were mostly satisfied with the telemedicine service.
-
Citations
Citations to this article as recorded by - A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease
Jae Young Joo, Ji Young Yun, Young Eun Kim, Yu Jin Jung, Ryul Kim, Hui-Jun Yang, Woong-Woo Lee, Aryun Kim, Han-Joon Kim
Journal of Movement Disorders.2024; 17(1): 89. CrossRef - Expert teleconsultation involving patients and their primary neurologists for the management of multiple sclerosis in regions without specialists
Yusei Miyazaki, Shigehisa Ura, Kazuhiro Horiuchi, Takeshi Matsuoka, Hideki Houzen, Kazufumi Tsuzaka, Yuichi Makino, Manami Koshida, Genko Oyama, Chika Sato, Ryoji Naganuma, Itaru Amino, Sachiko Akimoto, Masaaki Niino, Naoya Minami, Eri Takahashi, Susumu O
Clinical and Experimental Neuroimmunology.2024;[Epub] CrossRef - Effects of LSVT-BIG via telerehabilitation on non-motor and motor symptoms and quality of life in Parkinson’s disease
Yasemin Ekmekyapar Fırat, Türkan Turgay, Selver Seval Soğan, Pınar Günel Karadeniz
Acta Neurologica Belgica.2023; 123(1): 207. CrossRef - A Narrative Review of Current Status and Future Perspective of Telemedicine for Parkinson's Disease, Dementia, and Intractable Neurological Diseases in Japan
GENKO OYAMA, MAYUKO OGAWA, SATOKO SEKIMOTO, TAKU HATANO, NOBUTAKA HATTORI
Juntendo Medical Journal.2023; 69(1): 14. CrossRef - A multicenter, prospective, observational study to assess the satisfaction of an integrated digital platform of online medical care and remote patient monitoring in Parkinson's disease
Makoto Shiraishi, Tsutomu Kamo, Ryuya Kumazawa, Naoshi Sasaki, Kenji Isahaya, Hisanao Akiyama, Yoshihiko Furusawa, Reiko Onodera, Jovelle Fernandez, Masaru Otsuka, Yoshihisa Yamano
Neurology and Clinical Neuroscience.2023; 11(3): 152. CrossRef - New era of artificial intelligence and machine learning-based detection, diagnosis, and therapeutics in Parkinson’s disease
Rohan Gupta, Smita Kumari, Anusha Senapati, Rashmi K. Ambasta, Pravir Kumar
Ageing Research Reviews.2023; 90: 102013. CrossRef - Feasibility study of Internet video-based speech-language activity for outpatients with primary progressive aphasia
Shinji Higashi, Yuko Koshibe, Takehiro Miyazaki, Ryohei Watanabe, Hanako Nakanome, Takeshi Inoue, Takashi Asada, Tetsuaki Arai, Kenjiro Ono
PLOS ONE.2023; 18(7): e0288468. CrossRef - Feasibility and efficacy of video-call speech therapy in patients with Parkinson's disease: A preliminary study
Hee Jin Chang, Jiae Kim, Jae Young Joo, Han-Joon Kim
Parkinsonism & Related Disorders.2023; 114: 105772. CrossRef - Perspectives on Telemedicine
彦光 大山, 信孝 服部
Iryou kikigaku (The Japanese journal of medical instrumentation).2022; 92(3): 331. CrossRef
- Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
-
Juan Miguel Pilar Bautista, Genko Oyama, Maierdanjiang Nuermaimaiti, Satoko Sekimoto, Fuyuko Sasaki, Taku Hatano, Kenya Nishioka, Masanobu Ito, Atsushi Umemura, Yuji Ishibashi, Yasushi Shimo, Nobutaka Hattori
-
J Mov Disord. 2020;13(1):57-61. Published online January 31, 2020
-
DOI: https://doi.org/10.14802/jmd.19051
-
-
6,431
View
-
158
Download
-
6
Web of Science
-
6
Crossref
-
Abstract
PDF
- Objective
The long-term efficacy of deep brain stimulation (DBS) for motor fluctuations in advanced Parkinson’s disease (PD) has been well established; however, motor fluctuations may recur over time despite multiple adjustments of DBS settings and medications.
Methods
We conducted a retrospective chart review of three patients for whom levodopa-carbidopa intestinal gel (LCIG) was additionally administered as a rescue therapy for secondary DBS failure due to the recurrence of motor fluctuations.
Results
The three patients had advanced PD with a disease duration of 14–19 years, and had undergone DBS for motor fluctuations refractory to standard medical management. LCIG was administered to the patients because of symptom recurrence years after DBS and provided complementary effects in all patients.
Conclusion
The cases presented here show that rescue LCIG therapy may be a complementary treatment option for patients with post-DBS advanced PD who have a recurrence of troublesome motor complications.
-
Citations
Citations to this article as recorded by - Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease
Dominik Pürner, Mohammad Hormozi, Daniel Weiß, Michael T. Barbe, Hannah Jergas, Tino Prell, Eileen Gülke, Monika Pötter-Nerger, Björn Falkenburger, Lisa Klingelhöfer, Pia K. Gutsmiedl, Bernhard Haslinger, Angela M. Jochim, Andreas Wolff, Nils Schröter, Mi
Neurology.2023;[Epub] CrossRef - Combining Device‐Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review
Iro Boura, Nikolaos Haliasos, Ιrene‐Areti Giannopoulou, Dimitrios Karabetsos, Cleanthe Spanaki
Movement Disorders Clinical Practice.2021; 8(5): 750. CrossRef - Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
Daniël van Poppelen, Annelie N.M. Tromp, Rob M.A. de Bie, Joke M. Dijk
Journal of Personalized Medicine.2021; 11(6): 547. CrossRef - Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
Valentina Leta, Haidar S. Dafsari, Anna Sauerbier, Vinod Metta, Nataliya Titova, Lars Timmermann, Keyoumars Ashkan, Michael Samuel, Eero Pekkonen, Per Odin, Angelo Antonini, Pablo Martinez-Martin, Miriam Parry, Daniel J. van Wamelen, K. Ray Chaudhuri
Journal of Personalized Medicine.2021; 11(8): 773. CrossRef - Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
Yassine Noui, Monty Adam Silverdale, Julian Evans, Lucy Partington-Smith, Christopher Kobylecki
Journal of Movement Disorders.2021; 14(3): 239. CrossRef - The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
Joke M. Dijk, Alberto J. Espay, Regina Katzenschlager, Rob M.A. de Bie, Bastiaan R. Bloem, Patrik Brundin
Journal of Parkinson's Disease.2020; 10(s1): S65. CrossRef
|
KMDS
E-submission
